(ZTS)

The S&P 500 has dropped 10% or more nine times since 2010, not including the current sell-off. However, the index has delivered an average return of 18% in the year following the start date of these c...

It's been a tough start to 2025 for investors amid concerns regarding the strength of the U.S. economy and uncertainties over the effect of sweeping changes in trade policy under the Trump administrat...

There are many dividend stocks on equity markets, but not all are attractive to income investors. Those that go beyond paying a quarterly payout but also consistently raise their dividends -- all whil...

My Top 15 High-Growth Dividend stocks outperformed SPY and VIG in March, posting a loss of 3.26% compared to SPY's 5.86% and VIG's 4.50%. The April 2025 list offers an average dividend yield of 1.25% ...

Shares in animal pharmaceutical company Zoetis (ZTS 0.14%) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but the ...

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck...

Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humaniza...

Zoetis (ZTS) closed the most recent trading day at $163.03, moving -0.08% from the previous trading session.

The latest trading day saw Zoetis (ZTS) settling at $160.06, representing a -1% change from its previous close.

The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela labe...